Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Brun-Vezinet

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Antiviral Therapy|January 26, 2002
Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapyM Mouroux, D Descamps, J Izopet, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2010
Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patientsLucile Larrouy, C Chazallon, R Landman, et al.
International Journal of Antimicrobial Agents|March 13, 1999
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trialA M Been-Tiktak, C A Boucher, F Brun-Vezinet, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 21, 2015
Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variantsM Noguera-Julian, A Cozzi-Lepri, F Di Giallonardo, et al.
HIV Medicine|August 25, 2010
Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study)M Zazzi, R Kaiser, A Sönnerborg, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Antiviral Therapy|January 26, 2002
Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapyM Mouroux, D Descamps, J Izopet, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2010
Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patientsLucile Larrouy, C Chazallon, R Landman, et al.
International Journal of Antimicrobial Agents|March 13, 1999
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trialA M Been-Tiktak, C A Boucher, F Brun-Vezinet, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 21, 2015
Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variantsM Noguera-Julian, A Cozzi-Lepri, F Di Giallonardo, et al.
HIV Medicine|August 25, 2010
Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study)M Zazzi, R Kaiser, A Sönnerborg, et al.
Pageof 9